Rajeev M. Menon

Rajeev M. Menon

Auto-generated profile, based on publicly available information

Rajeev M. Menon

AbbVie Inc. North Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Journal of Hepatology
Verified
Journal Article
Open access
RMRajeev M. Menon
Rajeev M. Menon
PBPrajakta S. Badri
Prajakta S. Badri
TWTianli Wang
Tianli Wang
APAkshanth R. Polepally
Akshanth R. Polepally
JZJiuhong Zha
Jiuhong Zha
SDSandeep Dutta
Sandeep Dutta
Paritaprevir (administered with ritonavir, PTV/r), ombitasvir (OBV), and dasabuvir (DSV) are direct-acting antiviral agents (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection. Thirteen studies were conducted to characterize drug-drug interactions for the 3D regimen of OBV, PTV/r, and DSV and various medications in healthy volunteers to inform dosing recommendations in HCV-infected patients. Mechanism-based drug-drug interactions were evaluated for gemfibrozil, ketoconazole, carbamazepine, warfarin, omeprazole, digoxin, pravastatin, and rosuvastatin. Drug-drug interactions with medications commonly used in HCV-infected patients were evaluated for amlodipine, furosemide, alprazolam, zolpidem, duloxetine, escitalopram, methadone, buprenorphine/naloxone, and oral contraceptives. Ratios of geometric means with 90% confidence intervals for maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) were used to determine the magnitude of interaction. Coadministration with the 3D regimen of OBV, PTV/r, and DSV resulted in a <2-fold change in mean Cmax and AUC for most medications and the DAAs, indicating minimal to modest interactions. Carbamazepine decreased PTV, ritonavir, and DSV exposures substantially, while gemfibrozil increased DSV exposures substantially. Although coadministration with ethinyl estradiol-containing contraceptives resulted in elevated alanine aminotransferase levels, coadministration with a progestin-only contraceptive did not. The majority of medications can be coadministered with the 3D regimen of OBV, PTV/r, and DSV without dose adjustment, or with clinical monitoring or dose adjustment. Although no dose adjustment is necessary for the 3D regimen when coadministered with 17 of the 20 medications, coadministration with gemfibrozil, carbamazepine, or ethinyl estradiol-containing contraceptives is contraindicated.

22 May 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
ASAhmed Hamed Salem
Ahmed Hamed Salem
RMRajeev M. Menon
Rajeev M. Menon
Venetoclax, a highly potent BCL‐2 inhibitor, is indicated for treatment of some hematologic malignancies as monotherapy, and/or in combination with other agents. Venetoclax pharmacokinetics has been extensively characterized in patients and healthy participants. After oral dosing, the median time to reach maximum plasma concentration ranged from 5 to 8 h and harmonic mean half‐life ranged from 14 to 18 h. Food increases venetoclax bioavailability by 3–5‐fold and venetoclax should be administered with food to ensure adequate and consistent bioavailability. Venetoclax is eliminated via cytochrome P450 (CYP)3A metabolism, and a negligible amount of unchanged drug is excreted in urine. Strong CYP3A/P‐glycoprotein inhibitors increased venetoclax exposures (AUC) by 1.44‐ to 6.90‐fold while a significant decrease (71%) has been observed when dosed with strong CYP3 inducers. Venetoclax does not inhibit or induce CYP enzymes or transporters. Venetoclax pharmacokinetics is not appreciably altered by age, weight, sex, but the exposure is up to twofold higher in participants from Asian countries. Mild‐to‐severe renal impairment or end‐stage renal disease do not alter venetoclax exposures, and venetoclax is not cleared by dialysis. Although mild‐to‐moderate hepatic impairment does not affect venetoclax exposures, twofold higher exposure was observed in subjects with severe hepatic impairment. Venetoclax exposure is comparable across patients with different hematologic malignancies and healthy participants. Overall, venetoclax exposure is only affected by food and CYP3A modulators and is only higher in Asian subjects and subjects with severe hepatic impairment. Venetoclax exposure–response relationships are malignancy‐dependent and can be different between monotherapy and combination therapy.

9 June 2015 in Journal of Hepatology
Verified
Journal Article
Closed access
PDF file
AKAmit Khatri
Amit Khatri
RMRajeev M. Menon
Rajeev M. Menon
TMThomas C. Marbury
Thomas C. Marbury
ELEric J. Lawitz
Eric J. Lawitz
TPThomas J. Podsadecki
Thomas J. Podsadecki
SDSandeep Dutta
Sandeep Dutta

28 December 2015 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
RMR. M. Menon
R. M. Menon
CKC. E. Klein
C. E. Klein
TPT. J. Podsadecki
T. J. Podsadecki
YCY.‐L. Chiu
Y.‐L. Chiu
SDS. Dutta
S. Dutta
WAW. M. Awni
W. M. Awni
Aims: Paritaprevir is a direct acting antiviral agent for use as part of a multidrug hepatitis C virus infection treatment regimen. To characterize the pharmacokinetics, safety, and tolerability of paritaprevir and determine an optimal dosing regimen for subsequent evaluations, clinical studies were conducted with paritaprevir alone or with ritonavir, a cytochrome P450 3A4 inhibitor anticipated to increase paritaprevir exposure.Methods: Two phase 1, double‐blind, placebo‐controlled, parallel group studies were conducted in healthy volunteers (NCT00850044 and NCT00931281). Single dose study participants (n = 87) were randomized to one time administration of either paritaprevir or placebo, or paritaprevir with ritonavir or placebo. Participants (n = 38) enrolled in the multiple dose study received paritaprevir with ritonavir or placebo once or twice daily for 14 days. Pharmacokinetics, safety and tolerability were assessed throughout the study treatment periods.Results: After single or multiple dose administration, paritaprevir displayed non‐linear pharmacokinetics, with maximum plasma concentration and area under the plasma concentration–time curve increasing in a greater than dose proportional manner. Concomitant administration of 100 mg ritonavir increased paritaprevir exposure from a 300 mg dose approximately 30‐ to 50‐fold and extended paritaprevir half‐life. The tolerability of paritaprevir was similar with or without ritonavir. Asymptomatic, transient increases in bilirubin were observed but were not associated with abnormalities in other liver function tests.Conclusions: Paritaprevir exhibits non‐linear pharmacokinetics with greater than dose proportional increases in exposure after single or multiple dosing. Co‐administration with ritonavir increases paritaprevir exposure and half‐life without adversely influencing tolerability.

1 May 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
AKAmit Khatri
Amit Khatri
SDSandeep Dutta
Sandeep Dutta
MDMartin Dunbar
Martin Dunbar
TPThomas Podsadecki
Thomas Podsadecki
RTRoger Trinh
Roger Trinh
RMRajeev Menon
Rajeev Menon
The three direct-acting antiviral agent (3D) regimen is a novel combination of direct-acting antiviral agents (DAAs) that has proven effective for the treatment of hepatitis C virus (HCV) infection. Given the potential for coadministration in patients with human immunodeficiency virus infection, possible drug interactions with antiretroviral drugs must be carefully considered. Four phase 1, multiple-dose pharmacokinetic studies were conducted in healthy volunteers ( n = 66). The 3D regimen of 150/100 mg daily paritaprevir/ritonavir, 25 mg daily ombitasvir, and 400 mg twice-daily dasabuvir was administered alone or in combination with 200 mg daily of emtricitabine and 300 mg daily of tenofovir disoproxil fumarate (tenofovir DF), 25 mg daily of rilpivirine, or 400 mg of raltegravir twice daily. A 2-DAA regimen of 150/100 mg daily paritaprevir/ritonavir and 400 mg of dasabuvir twice daily was also studied in combination with efavirenz/emtricitabine/tenofovir DF at 600/200/300 mg daily, respectively (Atripla; Bristol-Myers Squibb). Pharmacokinetic parameters were determined from plasma drug concentrations. No clinically significant drug interactions were observed (≤32% change in exposure) between the 3D regimen and that of emtricitabine plus tenofovir DF. Raltegravir exposure was increased up to 134% when the drug was coadministered with the 3D regimen. Although coadministration with rilpivirine was well tolerated in healthy volunteers, observed elevations in rilpivirine exposures may increase the potential for adverse drug reactions. Concomitant use of the 2-DAA regimen and efavirenz/emtricitabine/tenofovir DF was discontinued owing to poor tolerability and adverse events. No dose adjustment is required during coadministration of raltegravir, tenofovir DF, or emtricitabine with the 3D regimen. Rilpivirine is not recommended and efavirenz is contraindicated for coadministration with the 3D regimen.

1 October 2016 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
PBPrajakta S. Badri
Prajakta S. Badri
APApurvasena Parikh
Apurvasena Parikh
ECEoin P. Coakley
Eoin P. Coakley
BDBifeng Ding
Bifeng Ding
WAWalid M. Awni
Walid M. Awni
RMRajeev M. Menon
Rajeev M. Menon
Background: Interactions between tacrolimus and cyclosporine (CSA) and the 3 direct-acting antiviral regimen (3D) of ombitasvir, paritaprevir/ritonavir, and dasabuvir necessitate a priori dose adjustments for the immunosuppressants to achieve desired levels. Modeling and simulations based on data in healthy subjects predicted that tacrolimus 0.5 mg every 7 days or 0.2 mg every 3 days, and CSA at one-fifth the total daily dose administered once daily, would achieve desired trough concentrations (C trough) during 3D treatment. The success of these dosing recommendations was evaluated by analyzing pharmacokinetic data from liver transplant recipients in the CORAL-I study. Methods: A population pharmacokinetic model was developed using tacrolimus dosing and C trough data before and during 3D treatment (n = 29). The model was used to simulate various tacrolimus dosing regimens and predict tacrolimus concentration–time profiles during 3D treatment. CSA C trough data before and during 3D treatment (n = 5) were also summarized. Results: A one-compartment model with first-order absorption adequately described tacrolimus pharmacokinetic profiles during the first 4 weeks of 3D treatment. Estimated tacrolimus C trough values (median; interquartile range) before and during 3D treatment were comparable (5.7 ng/mL; 4.9–6.5 ng/mL versus 5.2 ng/mL; 4.2–6.3 ng/mL, respectively). Based on simulations, in a patient with a starting C trough of 6 ng/mL, 0.5 mg tacrolimus every 7 or 14 days or 0.2 mg tacrolimus every 3 days will result in C trough levels of 6–9 ng/mL, 4–6 ng/mL, and 6–10 ng/mL, respectively, during 3D treatment. For CSA, C trough values (median; interquartile range) before and during 3D treatment were comparable (126 ng/mL; 94–140 ng/mL versus 104 ng/mL; 82–140 ng/mL). Conclusions: Observed data for tacrolimus and CSA in liver transplant recipients confirm that the recommended dosing strategies are valid and therapeutic levels of immunosuppression can be maintained during 3D treatment.